% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Nov 28, 2011 2:46 PM Flag


    Hard to believe GILD would pay 11 billion for a phase II drug that may or may not be effective against GT1 Hep C. Someone at that company should have seen the huge red flags: 1) Testing PSI-7977 only against interferon intolerant GT1 patients. 2) Testing PSI-7977 against a mix of GT2/3 and GT1 patients rather than against GT1 patients alone. Given that the majority of U.S. patients are GT1, GILD is taking a huge gamble. The fact that Pharmasset is not doing a trial of PSI-7977/ribavirin against GT1 Hep C patients regardless of interferon tolerance tells you everything you need to know about their prospects in the Hep C market.

84.00+3.37(+4.18%)May 5 4:00 PMEDT